Stay updated on Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page shows a new revision label (Revision: v3.3.4) replacing the previous v3.3.3; no study content or critical UI changes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:21:31.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Added a Locations section listing Kanagawa and Osaka sites (Yokohama, Kanagawa; Osaka) and updated the page revision to v3.3.3; removed the HHS Vulnerability Disclosure and the Kanagawa/Osaka Location entries.
    Difference
    0.3%
    Check dated 2025-12-23T09:25:46.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Added a note that publications are automatically filled from PubMed and may not all be about the study, and added Revision: v3.3.2. Removed the previous PubMed publications description indicating the list is auto-generated by ClinicalTrials.gov Identifier (NCT Number) and removed Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-24T17:02:58.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Removed the funding/status notice banner that previously informed users about government operating status and NIH accessibility. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T15:05:19.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Minor updates to the page layout and timestamps, with no changes to trial interventions, endpoints, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:31:03.000Z thumbnail image
  8. Check
    105 days ago
    Change Detected
    Summary
    Significant updates add current operating status, newer revision/versioning, and fresh study details; older recruitment, contact, and historical publication data were removed to reflect current status.
    Difference
    9%
    Check dated 2025-10-05T10:31:28.000Z thumbnail image

Stay in the know with updates to Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.